CNBX Pharmaceuticals Inc.
CNBX
$0.00
$0.000.00%
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 429.50K | 307.10K | 298.80K | 271.60K | 268.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 429.50K | 307.10K | 298.80K | 271.60K | 194.40K |
| Operating Income | -429.50K | -307.10K | -298.80K | -271.60K | -194.40K |
| Income Before Tax | -462.10K | -367.60K | -393.30K | -314.00K | -224.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.46 | -0.37 | -0.39 | -0.31 | -0.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -462.10K | -367.60K | -393.30K | -314.00K | -224.50K |
| EBIT | -429.50K | -307.10K | -298.80K | -271.60K | -194.40K |
| EBITDA | -111.70K | -134.00K | -180.70K | -199.50K | -140.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 3.24B | 1.96B | 1.06B | 361.98M | 136.90M |
| Average Diluted Shares Outstanding | 3.24B | 1.96B | 1.06B | 361.98M | 136.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |